Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects Using Four Different Vaccination Shedules.

Trial Profile

Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects Using Four Different Vaccination Shedules.

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Dec 2016

At a glance

  • Drugs Influenza A virus vaccine-H5N1; MF 59
  • Indications Influenza A virus H5N1 subtype
  • Focus Pharmacodynamics; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 02 Oct 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov
    • 23 Feb 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top